AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Theglobeandmail

Published November 12, 2026

UFC Hall of Famer Michael Bisping Backs Xycota Biosciences' Low-Dose Psilocybin ...

Read the full story at Theglobeandmail

ACCESS Newswire Press Release ... psychedelic effects, with the clinical dose still to be determined. Its first planned clinical target is mild.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelic press release